Accept Refuse

EUR-Lex Access to European Union law

This document is an excerpt from the EUR-Lex website

Document 22018D1758

Decision of the EEA Joint Committee No 24/2017 of 3 February 2017 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2018/1758]

OJ L 297, 22.11.2018, p. 30–30 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

In force

ELI: http://data.europa.eu/eli/dec/2018/1758/oj

22.11.2018   

EN

Official Journal of the European Union

L 297/30


DECISION OF THE EEA JOINT COMMITTEE

No 24/2017

of 3 February 2017

amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2018/1758]

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (‘the EEA Agreement’), and in particular Article 98 thereof,

Whereas:

(1)

Commission Implementing Regulation (EU) 2016/1444 of 31 August 2016 amending Regulation (EU) No 37/2010 as regards the substance hydrocortisone aceponate (1) is to be incorporated into the EEA Agreement.

(2)

Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

The following indent is added in point 13 (Commission Regulation (EU) No 37/2010) of Chapter XIII of Annex II to the EEA Agreement:

‘—

32016 R 1444: Commission Implementing Regulation (EU) 2016/1444 of 31 August 2016 (OJ L 235, 1.9.2016, p. 8).’

Article 2

The text of Implementing Regulation (EU) 2016/1444 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.

Article 3

This Decision shall enter into force on 4 February 2017, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*1).

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.

Done at Brussels, 3 February 2017.

For the EEA Joint Committee

The President

Claude MAERTEN


(1)  OJ L 235, 1.9.2016, p. 8.

(*1)  No constitutional requirements indicated.


Top